Rofecoxib versus codeine/acetaminophen in postoperative dental pain: a double-blind, randomized, placebo- and active comparator—controlled clinical trial

Chang, David J.; Fricke, James R.; Bird, Steven R.; Bohidar, N. R.; Dobbins, Thomas W.; Geba, Gregory P.

doi:10.1016/s0149-2918(01)80119-3

Cited by 76 publications

(41 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One hour later -approximately two hours after administration of the study drug -a postdrug sample was obtained. The time interval for blood sampling was selected based upon documentation of analgesic efficacy within 45 min of oral ingestion of ROF 50 mg in patients experiencing dental pain 9 and within 75 min in patients receiving analgesia and sedation for nasal surgery, 13 as well as documentation of significant plasma levels by two hours after ingestion (with virtual bioequivalence of ROF in oral suspension and tablets). 14 The baseline (pre-study drug) and intraoperative (post-study drug) blood samples were prepared identically to generate platelet-rich plasma, which was adjusted to a platelet count of 250 × 10 9 ·L -1 as previously described.…”

Section: Objectifmentioning

confidence: 99%

“…Inhibition of the COX-2 isoform limits the synthesis of inflammatory and algesic mediators as may be released during tissue injury and thereby provides effective analgesia. 1,5,[9][10][11][12][13][20][21][22] However, nonselective NSAIDs have not been uniformly embraced as perioperative analgesics, primarily because of potentially undesirable binding to the COX-1 isoform. Inhibition of this isoform prevents such constitutive physiologic functions as generation of thromboxane (for vasoconstriction and platelet-derived hemostasis) and maintenance of gastrointestinal mucosal integrity.…”

Section: Objectifmentioning

confidence: 99%

See 1 more Smart Citation

Rofecoxib does not compromise platelet aggregation during anesthesia and surgery

Silverman

Halaszynski

Sinatra

et al. 2003

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

show abstract

Section: Objectifmentioning

confidence: 99%

Section: Objectifmentioning

confidence: 99%

Rofecoxib does not compromise platelet aggregation during anesthesia and surgery

Silverman

Halaszynski

Sinatra

et al. 2003

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

show abstract

“…Severity-duration measures have been used to assess the burden of illness imposed at the population level by mental disorders, 40 to compare injection site pain after vaccination with different vaccines, 37 and to assess postoperative dental pain. 3,26 . Harrison et al 16 used a related approach, a "mixed model" (person level model), to assess HZ pain severity over time in patients with human immunodeficiency virus.…”

mentioning

confidence: 99%

Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventory

Coplan

Schmader

Nikas

et al. 2004

The Journal of Pain

272

276

View full text Add to dashboard Cite

“…F urther, with respect to the duration of effect, the results can be somewhat misleading, as ibupr ofen and celecoxib require multiple daily doses (M oor e & H ersh 2001;Olszynski et al 2002). In another third molar postextraction model (Chang et al 2001), rofecoxib was found to have an analgesic efficacy greater than that of a combination of codeine 60 mg and paracetamol 600 mg (P < 0.001 for all measures of analgesic efficacy), with a lower incidence of nausea (P < 0.001) and other common adverse events (P < 0.05).…”

Section: Rofecoxibmentioning

confidence: 89%

Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects

Ahuja

Singh

2003

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Rofecoxib (MK-966) is a new generation non-steroidal anti-inflammatory agent (NSAID) that exhibits promising anti-inflammatory, analgesic and antipyretic activity. It selectively inhibits cyclooxygenase (COX)-2 isoenzyme in a dose-dependent manner in man. No significant inhibition of COX-1 is observed with rofecoxib up to doses of 1000 mg. The pharmacokinetics of rofecoxib has been found to be complex and variable. Mean oral bioavailability after single dose of rofecoxib (12.5, 25 or 50 mg) is 93% with t m a x varying widely between 2 and 9 h. It is highly plasma-protein bound and is metabolized primarily by cytosolic reductases to inactive metabolites. Rofecoxib is eliminated predominantly by hepatic metabolism with a terminal half-life of approximately 17 h during steady state. Various experimental models and clinical studies have demonstrated rofecoxib to be superior, or at least equivalent, in anti-inflammatory, analgesic and antipyretic efficacy to comparator nonselective NSAIDs in osteoarthritis, rheumatoid arthritis and other pain models. Emerging evidence suggests that rofecoxib may also find potential use as supportive therapy in various pathophysiologic conditions like Alzheimer's disease, and in various malignant tumours and polyps, where COX-2 is overly expressed. Rofecoxib is generally well-tolerated. Analysis of data pooled from several trials suggests that rofecoxib is associated with fewer incidences of clinically symptomatic gastrointestinal ulcers and ulcer complications vis-a Á -vis conventional NSAIDs. However, this gastropreserving effect may be negated by concurrent use of low-dose aspirin for cardiovascular risk reduction. Rofecoxib tends to show similar tolerability for renal and cardiothrombotic events as compared with nonnaproxen nonselective NSAIDs. No clinically significant drug interaction has been reported for rofecoxib except with diuretics, where it reverses their salt-wasting effect and thus can be clinically exploited in electrolyte-wasting disorders. There is only modest information about the physicochemical and pharmaceutical aspects of rofecoxib. Being poorly water soluble, its drug delivery has been improved using varied formulation approaches. Although it is stable in solid state, rofecoxib is photosensitive and base-sensitive in solution form with its degradation mechanistics elucidated. Analytical determinations of rofecoxib and its metabolites in biological fluids employing HPLC with varied types of detectors have been reported. Isolated studies have also been published on the chromatographic and spectrophotometric assay of rofecoxib and its degradants in bulk samples and pharmaceutical dosage forms. The current article provides an updated overview on the physicochemical, pharmaceutical, pharmacokinetic and pharmacodynamic vistas of rofecoxib.

show abstract

Rofecoxib versus codeine/acetaminophen in postoperative dental pain: a double-blind, randomized, placebo- and active comparator—controlled clinical trial

Cited by 76 publications

References 9 publications

Rofecoxib does not compromise platelet aggregation during anesthesia and surgery

Rofecoxib does not compromise platelet aggregation during anesthesia and surgery

Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventory

Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects

Contact Info

Product

Resources

About